Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at TD Cowen’s 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, 11:50 AM - 12:20 PM ET.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.candeltx.com, and a replay will be archived for up to 90 days after the session.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: CAPR up 3.01%, IMMP up 4.17%, NMRA down 6.09%. Another peer, ANNX, also disclosed TD Cowen conference participation, suggesting company-specific investor-relations activity rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Public offering priced | Negative | +1.7% | Priced 18,348,624-share offering at $5.45 to raise about $100M. |
| Feb 19 | Offering proposed | Negative | +0.0% | Proposed $100M common stock offering under existing shelf registration. |
| Feb 19 | Royalty funding deal | Positive | +0.0% | $100M RTW royalty funding tied to CAN‑2409 prostate cancer launch. |
| Feb 11 | Scientific conference | Neutral | -4.0% | Company presentations at Glioblastoma Drug Development Summit in Boston. |
| Feb 02 | Inducement grants | Neutral | +0.8% | Inducement stock options for one new employee under 2025 Plan. |
Recent CADL news often shows price moves that diverge from the intuitive sentiment of the announcements, including offerings and funding deals.
Over recent weeks, Candel announced several capital-related milestones, including a public offering of 18,348,624 shares at $5.45 per share expected to raise about $100 million, and a separate proposed $100 million offering. It also disclosed a $100 million royalty funding agreement tied to CAN‑2409, plus participation in scientific conferences and inducement option grants. Against this backdrop of financing and scientific visibility, today’s TD Cowen conference appearance continues an active investor- and science-outreach cadence.
Regulatory & Risk Context
Candel has an effective Form S-3 shelf filed on Aug 14, 2025 to offer up to $300,000,000 of securities, including up to $50,000,000 via an at-the-market agreement with Jefferies LLC. The shelf has been used recently via 424B5 offerings on Feb 19 and Feb 20, 2026, indicating available capacity for further capital raises.
Market Pulse Summary
This announcement highlights Candel’s participation at TD Cowen’s 46th Annual Health Care Conference, with management presenting on March 3, 2026 and providing a webcast archived for 90 days. It follows recent capital-raising and royalty funding steps supporting CAN‑2409 and other programs. Investors may watch for any updated commentary on clinical progress, commercialization plans, and use of the existing shelf capacity of up to $300,000,000 disclosed in prior filings.
Key Terms
clinical-stage medical
biopharmaceutical medical
immunotherapies medical
webcast technical
AI-generated analysis. Not financial advice.
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA.
Presentation Details:
Date: Tuesday, March 3, 2026
Time: 11:50 AM - 12:20 PM ET
Webcast Link: TD Cowen / Candel Presentation
A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section at www.candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
FAQ
When will Candel Therapeutics (CADL) present at TD Cowen’s 46th Annual Health Care Conference?
How can investors watch the CADL presentation webcast on March 3, 2026?
Who is presenting for Candel Therapeutics (CADL) at the TD Cowen conference?
Will the CADL presentation webcast be available after March 3, 2026 and for how long?
Does the announcement specify the topics Candel (CADL) will cover at TD Cowen on March 3, 2026?
